Description A blend of Tesamorelin (5mg) and Ipamorelin (5mg) studied for its role in regulating growth hormone (GH) secretion. Tesamorelin, a GHRF analog, has been researched for its effects on GH production and lipid metabolism. Ipamorelin interacts with the ghrelin receptor, influencing GH release while minimizing interactions with other endocrine pathways. This combination has been explored for its potential impact on metabolic processes and tissue studies. Commonly utilized in controlled research settings to evaluate GH-related responses.
